Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - GBP (£)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenue £ 3,844,532
Operating expenses:    
Research and development expenses 7,771,391 7,592,470
Administrative expenses 6,467,932 7,030,972
Administrative expenses - costs related to preparing for listing 1,305,087
Total operating expenses 14,239,323 15,928,529
Loss from operations (14,239,323) (12,083,997)
Other income (expense):    
Loss on modification of convertible loan (645,845) (140,344)
Change in fair value of derivative liability 8,052,581 16,064,945
Foreign currency losses (80,070) (120,974)
Interest expense (83,025) (6,753,231)
Total other income (expense), net 7,243,641 9,050,396
Net loss before income taxes (6,995,682) (3,033,601)
Income tax credit 1,088,729 1,720,000
Net loss £ (5,906,953) £ (1,313,601)
Weighted-average ordinary shares outstanding - basic [1] 6,178,423 687,199
Weighted-average ordinary shares outstanding - diluted [1] 6,178,423 687,199
Basic net loss per share £ (0.96) £ (1.91)
Diluted net loss per share £ (0.96) £ (1.91)
[1] On November 18, 2022, the Company completed a reverse stock split of one (1) new share for every fifty (50) existing shares effective November 21, 2022. As a result of the share split, all references in these financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share split for all periods presented. In addition, the exercise prices and the numbers of ordinary shares issuable upon the exercise of any outstanding options to purchase ordinary shares were proportionally adjusted pursuant to the respective anti-dilution terms of the share-based payment plans.